Creation of the Biobank Related to Eye Disease (BioBank)

This study is currently recruiting participants.
Verified May 2011 by William Beaumont Hospitals
Sponsor:
Collaborator:
Vision Research Foundation
Information provided by (Responsible Party):
Kimberly Drenser, William Beaumont Hospitals
ClinicalTrials.gov Identifier:
NCT01240343
First received: November 10, 2010
Last updated: November 6, 2012
Last verified: May 2011

November 10, 2010
November 6, 2012
June 2009
June 2014   (final data collection date for primary outcome measure)
To build the platform for a novel application of translational research that links cutting edge molecular laboratory techniques to clinical outcome studies [ Time Frame: unknown ] [ Designated as safety issue: No ]
Biobanks can be used for numberous discovery applications such as: identification and structural characterization of human genes, expression analysis, or discovery proteomics. Biological specimens, when coupled with standardized treatment and outcome data, will be essential resources for the identification, characterization and validation of biomarkers that are predictive of disease and treatment.
Same as current
Complete list of historical versions of study NCT01240343 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Creation of the Biobank Related to Eye Disease
Creation of the Biobank Related to Eye Disease

The purpose of this study is to develop a BioBank (a specialized lab) and collect blood, fluids and/or other tissue samples to study eye diseases.

The purpose of the Biobank related to eye disease at Beaumont Hospital is to help connect specialties and Specialists with each other, outside traditional limits of hospital or laboratory departments. The specimens (blood, fluids, and/or tissue samples) that will be collected from men, women and children will assist the researchers in a variety of studies on human eye diseases.

Research utilizing these specimens will allow for an increased understanding of the etiology, disease process, and response to treatments for various eye diseases, and will provide opportunities to subsequently improve our management decisions. Furthermore, projects that cross over between subspecialties are sparse and that is a limiting factor for the development of research that takes a more comprehensive approach.

Observational
Time Perspective: Prospective
Not Provided
Retention:   Samples With DNA
Description:

blood, urine other body fluids (i.e. vitreous)

Non-Probability Sample

All pediatric and adult patients (age 0-99)who are being seen in the eye Dr. office and or having eye surgery

Eye Diseases
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
2000
June 2020
June 2014   (final data collection date for primary outcome measure)

Inclusion Criteria: All pediatric and adult patients age 0-99 years -

Exclusion Criteria: All patients who do not agree to consent for collection of blood, fluids, tissue.

Patients who are cognitively impaired and are not able to verbalize understanding of the risks/benefits.

-

Both
Not Provided
Yes
Contact: Kimberly Drenser, MD, PhD 248-288-2280 kdrenser@arcpc.net
United States
 
NCT01240343
2009-057
No
Kimberly Drenser, William Beaumont Hospitals
Kimberly Drenser
Vision Research Foundation
Principal Investigator: Kimberly Drenser, MD, PhD Associated Retinal Consultants, P.C.
William Beaumont Hospitals
May 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP